PDCD1 and melanoma: Taken together, we have developed risk models based on the easily accessible clinicodemographical characteristics and routinely tested laboratory test results that have well-distinguished the Asian advanced melanoma patients with different survival and best response outcomes treated with the anti-PD-1 monotherapy, providing important survival information for patients within different risk subcategories.